ArticlePLoS neglected tropical diseases2026
Disclosing pathogenic processes of monkeypox (MPOX) and drug repurposing through host-transcriptomics analysis.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (MPOX) virus infection outbreak in Africa in 2022 was initially considered a neglected tropical disease (NTD). Now it is recognized as a global health problem. The recent global spread has emphasized the need for increased attention to combat MPOX. Although there are some vaccines against MPOX, most people worldwide are still not vaccinated due to their unawareness or unavailability. However, so far, there is no approved drug against MPOX yet. Therefore, effective drugs against MPOX are also essential. This study attempted to disclose pathogenic processes and therapeutic strategies of MPOX based on MPOX-associated host key-genes (hKGs). At first, three transcriptomic profile datasets were analyzed, identifying 166 common host differentially expressed genes (hDEGs) between MPOX patients and control groups, comprising 75 upregulated and 91 downregulated hDEGs. Subsequently, six top-ranked host key genes (hKGs): ALB, HSP90AA1, CDH1, PTPRC, IGF1, and ABL1, were identified as potential MPOX-causing genes through protein-protein interaction (PPI) network analysis. Functional enrichment analysis of these hKGs revealed critical pathogenic processes of MPOX infection, including biological processes, molecular functions, cellular components, and KEGG pathways. Regulatory network analysis involving transcription factors and miRNAs provided further insights into disease mechanisms. Based on molecular docking analysis, five top-ranked drug molecules Tecovirimat, Beclabuvir, Maraviroc, Raltegravir, and Brincidofovir were identified as potential repurposable therapeutics against MPOX. ADME/T and drug-likeness evaluations confirmed favorable pharmacokinetic properties for these candidates. Additionally, 100 ns molecular dynamics (MD) simulations of the top three complexes (ALB-Tecovirimat, CDH1-Maraviroc, and PPARG-Beclabuvir) demonstrated strong binding stability, supported by RMSD, RMSF, and MM-GBSA results. Therefore, the results provided in this study might be potential resources for diagnosis and therapies of MPOX patients. However, the findings require experimental validation in wet lab for further confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.